Alterations in the Fibrinolytic Cascade Post-transplant: Evidence of a Bimodal Expression Pattern

Journal of Heart and Lung Transplantation

Volumn 26, Issue 5, 2007, Pages 494-497

  Benza, Raymond L ^a   Cavender, Matthew A ^a   Barchue, Joseph ^a   Tallaj, Jose A ^a   Bourge, Robert C ^a   Kirklin, James K ^b   Coffey, Christopher S ^c  

^a Nutrition Sciences and Medicine   (United States)

^b University of Alabama at Birmingham   (United States)

^c UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FIBRINOGEN; PLASMIN; PLASMINOGEN ACTIVATOR INHIBITOR 1;

ARTICLE; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DEMOGRAPHY; FIBRINOLYSIS; HEART TRANSPLANTATION; HUMAN; MAJOR CLINICAL STUDY; MORPHOLOGY; PRIORITY JOURNAL; PROSPECTIVE STUDY; STATISTICAL SIGNIFICANCE;

ADULT; ANALYSIS OF VARIANCE; CORONARY ARTERIOSCLEROSIS; FEMALE; FIBRINOGEN; FIBRINOLYSIS; GRAFT REJECTION; GRAFT SURVIVAL; HEART TRANSPLANTATION; HUMANS; MALE; MIDDLE AGED; PLASMINOGEN ACTIVATOR INHIBITOR 1; POSTOPERATIVE CARE; PREDICTIVE VALUE OF TESTS; PROBABILITY; PROGNOSIS; PROSPECTIVE STUDIES; RISK ASSESSMENT;

EID: 34247107540     PISSN: 10532498     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.healun.2007.02.003     Document Type: Article

References (36)

1. Costanzo M.R., Naftel D.C., Pritzker M.R., et al. Heart transplant coronary artery disease detected by coronary angiography: a multiinstitutional study of preoperative donor and recipient risk factors. J Heart Lung Transplant 17 (1998) 744-753
2. Kobashigawa J.A., Tobis J.M., and Starling R.C. Multicenter intravascular ultrasound validation study among heart transplant recipients: outcomes after five years. J Am Coll Cardiol 3 (2005) 1532-1537
3. O'Neill B.J., Pflugfelder P.W., Singh M.R., Menkin A.H., McKenzie F.N., and Kostuk W.J. Frequency of angiographic detection and quantitative assessment of coronary arterial disease one and three years after cardiac transplantation. Am J Cardiol 63 (1989) 1221-1226
4. Mullins P.A., Shapiro L.M., Aravot D.A., et al. Experience of percutaneous transluminal coronary angioplasty in orthotopic cardiac transplant recipients. Eur Heart J 12 (1991) 1205-1207
5. Balk A.H., Simmons M.L., van den Linden M.J., et al. Coronary artery disease after heart transplantation: timing of coronary arteriography. J Heart Lung Transplant 12 (1993) 89-99
6. Gao S.-Z., Schroeder J.S., Alderman E.L., et al. Prevalence of accelerated coronary artery disease in heart transplant survivors. Comparison of cyclosporine and azathioprine regimens. Circulation 80 (1989) 100-105
7. Sandhu J.S., Uretsky B.F., Reddy P.S., et al. Potential limitations of percutaneous transluminal coronary angioplasty in heart transplant recipients. Am J Cardiol 69 (1992) 1234-1237
8. Ventura H.O., Ramee S.R., Jain A., et al. Coronary artery imaging with intravascular ultrasound in patients following cardiac transplantation. Transplantation 53 (1992) 216-219
9. Olivari M.T., Holman D.C., Wilson R.F., Kubo S.H., and Ring W.S. Coronary artery disease in cardiac transplant patients receiving triple-drug immunosuppressive therapy. Circulation 80 (1989) 111-115
10. Gao S.Z., Schroeder J.S., Hunt S., and Stinson E.B. Retransplantation for severe accelerated coronary artery disease in heart transplant recipients. Am J Cardiol 62 (1988) 876-881
11. Smith J.A., Ribakove G.H., Hunt S.A., et al. Heart retransplantation: the 25-year experience at a single institution. J Heart Lung Transplant 14 (1995) 832-839
12. Benza R.L., Grenett H.E., Bourge R.C., et al. Gene polymorphisms for PAI-1/t-PA and development of allograft coronary artery disease. Circulation 98 (1998) 2248-2254
13. Benza R.L., Anderson P.G., Lyle K., et al. Donor PAI-1 expression inhibits the intimal response of early allograft vascular disease. J Heart Lung Transplant 22 (2003) 515-518
14. Labarrere C.A., Pitts D., Halbrook H., and Faulk W.P. Tissue plasminogen activator, plasminogen activator inhibitor-1, and fibrin as indexes of clinical course in cardiac allograft recipients: an immunocytochemical study. Circulation 89 (1994) 1599-1608
15. Labarrere C.A., Nelson D.R., and Faulk W.P. Myocardial fibrin deposits in the first month after transplantation predict subsequent coronary artery disease and graft failure in cardiac allograft recipients. Am J Med 105 (1998) 207-213
16. Moons L., Shi C., Ploplis V., et al. Reduced transplant arteriosclerosis in plasminogen-deficient mice. J Clin Invest 102 (1998) 1788-1797
17. Bieber C.P., Stinson E.B., Shumway N.E., Payne R., and Kosek J. Cardiac transplantation in man. VII. Cardiac allograft pathology. Circulation 41 (1970) 753-772
18. Johnson D.E., Gao S.Z., Schroeder J.S., DeCampli W.M., and Billingham M.E. The spectrum of coronary artery pathologic findings in human cardiac allografts. J Heart Transplant 8 (1989) 349-359
19. Uys C.J., and Rose A.G. Pathologic findings in long-term cardiac transplants. Arch Pathol Lab Med 108 (1984) 112-116
20. Kapadia S.R., Ziada K.M., L'Allier P.L., et al. Intravascular ultrasound imaging after cardiac transplantation: advantage of multi-vessel imaging. J Heart Lung Transplant 19 (2000) 167-172
21. Brodsky S., Chen J., Lee A., Akassoglou K., Norman J., and Goligorsky M.S. Plasmin-dependent and -independent effects of plasminogen activators and inhibitor-1 on ex vivo angiogenesis. Am J Physiol Heart Circ Physiol 281 (2001) H1784-H1792
22. Chapman H.A. Plasminogen activators, integrins, and the coordinated regulation of cell adhesion and migration. Curr Opin Cell Biol 9 (1997) 714-724
23. Loskutoff D.J., and Quigley J.P. PAI-1, fibrosis, and the elusive provisional fibrin matrix. J Clin Invest 106 (2000) 1441-1443
24. Ploplis V.A., and Castellino F.J. Nonfibrinolytic functions of plasminogen. Methods 21 (2000) 103-110
25. Billingham M.E. Cardiac transplant atherosclerosis. Transplant Proc 19 (1987) 19-24
26. Shimizu H., Takahashi M., Takeda S., et al. Mycophenolate mofetil prevents transplant arteriosclerosis by direct inhibition of vascular smooth muscle cell proliferation. Transplantation 77 (2004) 1661-1667
27. Scheller B., Grandt A., Wnendt S., Lorenz G., Bohm M., and Nickenig G. Comparative study of tacrolimus and paclitaxel stent coating in the porcine coronary model. Z Kardiol 94 (2005) 445-452
28. Benza R.L., Brown R.N., Kirklin J.K., et al. Palliation of allograft vasculopathy with transluminal angioplasty-a decade of experience. J Heart Lung Transplant 21 (2002) 74-75
29. Patrassi G.M., Sartori M.T., Rigotti P., et al. Reduced fibrinolytic potential one year after kidney transplantation. Relationship to long-term steroid treatment. Transplantation 59 (1995) 1416-1420
30. Vathsala A., Weinberg R.B., Schoenberg L., et al. Lipid abnormalities in cyclosporine-prednisone-treated renal transplant recipients. Transplantation 48 (1989) 37-43
31. Verpooten G.A., Cools F.J., Van der Planken M.G., et al. Elevated plasminogen activator inhibitor levels in cyclosporin-treated renal allograft recipients. Nephrol Dial Transplant 11 (1996) 347-351
32. Yusuf S., Sleight P., Pogue J., Bosch J., Davies R., and Dagenais G. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med 342 (2000) 145-153
33. Kato T., Chan M.C., Gao S.Z., et al. Glucose intolerance, as reflected by hemoglobin A1c level, is associated with the incidence and severity of transplant coronary artery disease. J Am Coll Cardiol 43 (2004) 1034-1041
34. Bastard J.P., Pieroni L., and Hainque B. Relationship between plasma plasminogen activator inhibitor 1 and insulin resistance. Diabetes Metab Res Rev 16 (2000) 192-201
35. Paparella D., Brister S.J., and Buchanan M.R. Coagulation disorders of cardiopulmonary bypass: a review. Intensive Care Med 30 (2004) 1873-1881
36. Linden M.D. The hemostatic defect of cardiopulmonary bypass. J Thromb Thrombol 16 (2003) 129-147